A new class of rhomboid protease inhibitors discovered by activity-based fluorescence polarization.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23991088.
- Also identified by DOI 10.1371/journal.pone.0072307 and PMC identifier 3750051.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Rhomboids are intramembrane serine proteases that play diverse biological roles, including some that are of potential therapeutical relevance. Up to date, rhomboid inhibitor assays are based on protein substrate cleavage. Although rhomboids have an overlapping substrate specificity, substrates cannot be used universally. To overcome the need for substrates, we developed a screening assay using fluorescence polarization activity-based protein profiling (FluoPol ABPP) that is compatible with membrane proteases. With FluoPol ABPP, we identified new inhibitors for the E. coli rhomboid GlpG. Among these was a structural class that has not yet been reported as rhomboid inhibitors: β-lactones. They form covalent and irreversible complexes with the active site serine of GlpG. The presence of alkyne handles on the β-lactones also allowed activity-based labeling. Overall, these molecules represent a new scaffold for future inhibitor and activity-based probe development, whereas the assay will allow inhibitor screening of ill-characterized membrane proteases.
Medical subject headings
- DNA-Binding Proteins
- Drug Discovery
- Escherichia coli Proteins
- Fluorescence Polarization
- Membrane Proteins
- Protease Inhibitors